HomeCompareLVVP vs MRK

LVVP vs MRK: Dividend Comparison 2026

LVVP yields 38.10% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVVP wins by $152.1K in total portfolio value
10 years
LVVP
LVVP
● Live price
38.10%
Share price
$5.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$208.9K
Annual income
$33,891.10
Full LVVP calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — LVVP vs MRK

📍 LVVP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVVPMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVVP + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVVP pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVVP
Annual income on $10K today (after 15% tax)
$3,238.10/yr
After 10yr DRIP, annual income (after tax)
$28,807.43/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, LVVP beats the other by $20,479.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVVP + MRK for your $10,000?

LVVP: 50%MRK: 50%
100% MRK50/50100% LVVP
Portfolio after 10yr
$132.8K
Annual income
$21,844.62/yr
Blended yield
16.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LVVP
No analyst data
Altman Z
1.4
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVVP buys
0
MRK buys
0
No recent congressional trades found for LVVP or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVVPMRK
Forward yield38.10%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$208.9K$56.8K
Annual income after 10y$33,891.10$9,798.13
Total dividends collected$154.9K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LVVP vs MRK ($10,000, DRIP)

YearLVVP PortfolioLVVP Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,510$3,809.52$11,206$366.19+$3.3KLVVP
2$20,691$5,165.83$12,650$502.35+$8.0KLVVP
3$29,024$6,884.70$14,407$694.19+$14.6KLVVP
4$40,081$9,025.64$16,585$967.82+$23.5KLVVP
5$54,536$11,648.73$19,342$1,363.89+$35.2KLVVP
6$73,166$14,812.69$22,913$1,947.19+$50.3KLVVP
7$96,860$18,572.81$27,662$2,823.89+$69.2KLVVP
8$126,620$22,978.99$34,159$4,173.35+$92.5KLVVP
9$163,557$28,073.84$43,337$6,308.80+$120.2KLVVP
10$208,897$33,891.10$56,776$9,798.13+$152.1KLVVP

LVVP vs MRK: Complete Analysis 2026

LVVPStock

Lightstone Value Plus REIT V, Inc. (which may be referred to as the "Company," "we," "us," or "our"), was organized as a Maryland corporation on January 9, 2007 and has elected to be taxed, and currently qualifies, as a real estate investment trust ("REIT") for federal income tax purposes. The Company was formed primarily to acquire and operate commercial real estate and real estate-related assets on an opportunistic and value-add basis. In particular, the Company has focused generally on acquiring commercial properties with significant possibilities for capital appreciation, such as those requiring development, redevelopment, or repositioning, those located in markets and submarkets with high growth potential, and those available from sellers who are distressed or face time-sensitive deadlines. The Company has acquired a wide variety of commercial properties, including office, industrial, retail, hospitality, multifamily and student housing. The Company has purchased existing, income-producing properties, and newly-constructed properties. The Company has also invested in other real estate-related investments such as mortgage and mezzanine loans. The Company intends to hold the various real properties in which it has invested until such time as its board of directors determines that a sale or other disposition appears to be advantageous to achieve the Company's investment objectives or until it appears that the objectives will not be met. The Company currently has one operating segment. As of September 30, 2023, the Company had eight wholly owned real estate investments (multifamily properties) and one real estate-related investment (note receivable).

Full LVVP Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this LVVP vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVVP vs SCHDLVVP vs JEPILVVP vs OLVVP vs KOLVVP vs MAINLVVP vs JNJLVVP vs ABBVLVVP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.